Postpartum depression is the most common psychiatric complication of childbirth, affecting roughly 17.2 percent of women worldwide, and its consequences can be devastating: studies suggest that about 20 percent of postpartum deaths are linked to suicide associated with the condition. Yet the drugs available to treat it remain deeply imperfect. The first targeted medication, brexanolone, approved by the FDA in 2019, requires a 60-hour intravenous infusion in a monitored clinical facility and costs around $36,000 on average. Its oral successor, zuranolone, approved in 2023, carries higher rates of adverse events than placebo, including somnolence, dizziness and headache. Against this backdrop, a new rat study offers a strikingly simple candidate: bergamot essential oil, the fragrant extract of Citrus bergamia fruit, delivered by ordinary inhalation. The research, published in a peer-reviewed journal, reports that inhaled bergamot oil not only treated depressive-like behaviours in a rodent model of postpartum depression but, remarkably, prevented them when administered before the depressive state emerged.

The team used the internationally recognized hormone-simulated pseudopregnancy method, in which female Sprague Dawley rats were first ovariectomized and then given subcutaneous injections of oestradiol benzoate and progesterone for 23 days to mimic the hormonal state of pregnancy. Low-dose oestradiol (2.5 micrograms per rat daily) was paired with high-dose progesterone (4 milligrams daily) for the first 16 days, followed by a sharp rise in oestradiol to 50 micrograms daily. Abrupt cessation of hormone administration then simulates the sudden hormonal collapse of childbirth, triggering measurable depressive-like and anxiety-like behaviours two days later. Rats were divided into six groups: untreated controls, sham-surgery animals, the postpartum depression model group, a fluoxetine-treated comparison group receiving the standard SSRI at 10 milligrams per kilogram daily, a therapeutic bergamot group, and—critically—a prophylactic bergamot group that inhaled a 2.5 percent oil emulsion for one hour daily throughout the entire hormone-simulation period, before any depressive phenotype appeared.

The oil itself was rigorously characterized. Extracted by steam distillation from fresh bergamot fruit and analysed by gas chromatography–mass spectrometry, it contained 15 identified constituents, dominated by limonene (61.69 percent), γ-terpinene (28.02 percent), α-pinene (3.52 percent), β-pinene (2.80 percent) and α-phellandrene (1.28 percent). These five major components accounted for 97.31 percent of the total volatile content. Behavioural testing then delivered the study’s first headline result. On the sucrose preference test, a measure of anhedonia, model rats showed significantly reduced preference for sweet solution compared with controls and shams, while the therapeutic bergamot, prophylactic bergamot and fluoxetine groups all reversed this deficit. The open field test revealed that model rats travelled significantly shorter total distances, and the elevated plus maze showed reduced open-arm exploration and increased closed-arm time, classic signatures of anxiety. All three treatment groups normalized these parameters, with no significant differences among bergamot and fluoxetine groups.

With behaviour established, the researchers turned to the hippocampus, the brain region governing emotional regulation and memory that is highly vulnerable to stress and inflammation. Nissl staining, which visualizes the ribosome-rich structures responsible for protein synthesis in neurons, revealed significantly reduced Nissl body counts in the CA1, CA2, CA3 and dentate gyrus subregions of model rats. Both bergamot regimens restored Nissl substance across all subregions, indicating neuronal recovery. The team then probed the molecular machinery of synaptic plasticity using immunohistochemistry and Western blotting. PSD-95, a postsynaptic scaffolding protein essential for glutamatergic synapse maturation and excitatory transmission, was significantly depleted in all hippocampal subregions of model rats. Synaptophysin, a presynaptic vesicle protein required for neurotransmitter release, was similarly reduced. The prophylactic bergamot group upregulated PSD-95 across all regions, while both bergamot groups significantly increased synaptophysin—outperforming fluoxetine in the CA1 and CA2 subregions.

The biomarker data revealed the likely mechanism. Enzyme-linked immunosorbent assays quantified three molecules selected for their established roles in postpartum depression pathophysiology. Insulin-like growth factor-1, low levels of which in early pregnancy predict postpartum depression risk in human mothers according to the Japan Environment and Children’s Study and the Pomeranian Health Study, was significantly reduced in the serum and cerebrospinal fluid of model rats. Both bergamot regimens restored IGF-1 in these compartments—and the prophylactic group surpassed fluoxetine significantly. Interleukin-1β, a pro-inflammatory cytokine consistently elevated in postpartum depression and capable of disrupting the blood–brain barrier, was significantly increased in the serum and hippocampus of model rats; all treatments reduced it. Interleukin-10, the counter-regulatory anti-inflammatory cytokine that declines after delivery in women who develop postpartum depression, was significantly depleted in cerebrospinal fluid and restored by bergamot inhalation.

Molecular docking analysis added a tantalizing clue about which constituent might drive these effects. When the five major oil components were computationally docked against the five target proteins—PSD-95, synaptophysin, IL-1β, IGF-1 and IL-10—γ-terpinene emerged as the only component that successfully bound all five targets with low binding energy, suggesting strong, spontaneous affinity. The researchers note that γ-terpinene is also a prominent constituent of several other essential oils with documented antidepressant properties, including oregano oil, Hirami lemon oil and Picea mariana oil, where it ranks as the second major component. This consistent pattern across mood-modulating oils positions γ-terpinene as a plausible key active molecule, though the authors caution that the individual mechanisms of BEO’s constituents remain unexplored and that single-component validation is warranted before novel antidepressant development.

Safety findings were equally important for translation. Haematoxylin and eosin staining of the thymus and spleen—immune organs sensitive to systemic toxicity—showed preserved corticomedullary demarcation in the thymus and sharp red/white pulp boundaries in the spleen, with no significant histopathological differences between bergamot-treated groups and controls. Body weight remained unchanged across all groups throughout the experiment, indicating no metabolic disturbance. This favourable profile reflects bergamot’s dual delivery pathways: olfactory stimulation through the nasal epithelium enabling direct nose-to-brain transport that bypasses the blood–brain barrier, and respiratory absorption into systemic circulation. Inhaled constituents achieve rapid brain distribution and can modulate limbic structures including the amygdala and hippocampus, the thalamus and the prefrontal cortex—regions central to emotional regulation.

The prophylactic result is the study’s most consequential finding. Prenatal mood disorders are established independent risk factors for postpartum depression, and preventive interventions during pregnancy offer cost-effectiveness advantages, yet no current pharmacotherapy—SSRIs or neuroactive steroids—carries prophylactic utility for high-risk populations. In this experiment, bergamot inhalation during the hormone-simulation period, before any depressive phenotype appeared, successfully prevented synaptic deficits, preserved hippocampal neuronal integrity and suppressed neuroinflammation, achieving outcomes comparable to post-onset treatment while outperforming fluoxetine in elevating the neuroprotective IGF-1 biomarker. The authors argue this is the first study to establish a dual-phase bergamot intervention strategy combining prophylactic and therapeutic administration, positioning the oil as a practical candidate for prenatal prevention in high-risk women, particularly where pharmacotherapy access is limited.

Limitations temper the enthusiasm. The hormone-simulated pseudopregnancy model, while widely adopted, incompletely recapitulates the multifactorial aetiology of human postpartum depression; the authors propose combining genetic susceptibility models and social stress paradigms in future work. Because the rat model requires ovariectomy, teratogenicity testing during actual pregnancy could not be performed, meaning the safety of preventive inhalation during genuine gestation remains unverified. The study also relied on behavioural and molecular endpoints rather than human trials. Nevertheless, the convergence of behavioural rescue, synaptic restoration, inflammatory modulation, IGF-1 elevation and demonstrable systemic safety—delivered through a non-invasive, low-cost route—makes inhaled bergamot oil a compelling candidate for clinical translation. The authors conclude that future studies should prioritize human trials validating this dual-phase approach, potentially transforming a familiar fragrance into an accessible preventive regimen for one of motherhood’s most burdensome complications.

Subject of Research: Prophylactic Inhalation of Bergamot Essential Oil Ameliorates Hormone‐Simulated Pseudopregnancy Withdrawal‐Induced Postpartum Depression by Modulating Hippocampal Synaptic Plasticity

Article Title: Prophylactic Inhalation of Bergamot Essential Oil Ameliorates Hormone‐Simulated Pseudopregnancy Withdrawal‐Induced Postpartum Depression by Modulating Hippocampal Synaptic Plasticity

Article References: Xu, H., Zhang, S., He, H., Zhao, X., Cheng, Y., Wang, Y., Li, J., Yu, Y., Bian, Y., Guo, Y., & Zhang, M. (2026). Prophylactic Inhalation of Bergamot Essential Oil Ameliorates Hormone‐Simulated Pseudopregnancy Withdrawal‐Induced Postpartum Depression by Modulating Hippocampal Synaptic Plasticity. Journal of Cellular and Molecular Medicine, 30(20), Article e71395. https://doi.org/10.1111/jcmm.71395

Image Credits: AI Generated

DOI: 10.1111/jcmm.71395

Keywords: Prophylactic, Inhalation, Bergamot, Essential, Ameliorates, Hormone, Simulated, Pseudopregnancy, Withdrawal, Induced, Postpartum, Depression